Display Settings:

Format

Send to:

Choose Destination
JOP. 2009 Jul 6;10(4):393-5.

Sirolimus can reverse resistance to gemcitabine, capecitabine and docetaxel combination therapy in pancreatic cancer.

Author information

  • Columbia University, College Physicians and Surgeons, New York, NY, USA. whs4@columbia.edu

Abstract

CONTEXT:

Treating patients with metastatic carcinoma of the pancreas can lead to regression of disease, but the tumor becomes resistant to therapy within a few months. If resistance can be reversed or prevented, the chemotherapeutic benefit may be prolonged.

CASE REPORTS:

Two patients with metastatic pancreatic cancer progressed on gemcitabine, capecitabine and docetaxel (GTX). When sirolimus was added to this regimen at a dosage to achieve a serum level of at least 10 ng/dL at the time of the gemcitabine and docetaxel infusion, their tumors regressed.

CONCLUSION:

This demonstrates that the addition of sirolimus to a gemcitabine/docetaxel containing regimen can reverse tumor resistance in the clinical setting.

PMID:
19581741
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for JOP. Journal of the Pancreas (Online)
    Loading ...
    Write to the Help Desk